```html

Jamestown Syndrome (Acute Melioidosis)

Overview

Jamestown syndrome is a colloquial name for acute melioidosis, a bacterial infection caused by Burkholderia pseudomallei. The organism lives in soil and surface water in tropical and subtropical regions. When the bacteria enter the body through cuts, inhalation, or ingestion, they can cause a rapid‑onset, potentially life‑threatening illness that mimics pneumonia, septicemia, or abscess formation.

Who it affects: Historically, most cases have been reported in Southeast Asia and Northern Australia, but the disease is now recognized worldwide because of travel, military deployments, and climate‑change‑driven spread. In the United States, a small cluster of cases in the 1970s around Jamestown, Virginia, gave rise to the “Jamestown syndrome” nickname, though cases remain rare (<0.5 per 100,000 population).

Prevalence: The World Health Organization estimates 165,000–300,000 new melioidosis cases each year worldwide, with a case‑fatality rate of 10‑40 % depending on the setting and timeliness of treatment (WHO, 2021). In endemic regions, seroprevalence can reach 15‑20 % in agricultural workers.

Symptoms

Acute melioidosis often presents with a febrile illness that can involve many organ systems. The following list includes the most common and clinically important manifestations:

• Fever & chills – sudden onset, may be high‑grade.
• Headache – often dull, can be accompanied by neck stiffness if meningitis develops.
• Cough & sputum production – may progress to pneumonia; can be dry or purulent.
• Chest pain – pleuritic pain suggests pleural involvement.
• Shortness of breath – due to pulmonary infiltrates or empyema.
• Skin lesions – painless ulcer or abscess at the site of inoculation; may develop necrotic centers.
• Muscle and joint pain – can mimic septic arthritis.
• Abdominal pain – hepatic or splenic abscesses can cause right upper quadrant discomfort.
• Nausea, vomiting, diarrhea – gastrointestinal involvement is common.
• Confusion or altered mental status – indicates central nervous system infection or severe sepsis.
• Septic shock – hypotension, tachycardia, and multi‑organ failure in the most severe cases.

Symptoms typically appear 1–21 days after exposure, with a median incubation of 5 days. The disease can progress quickly; therefore, early recognition is crucial.

Causes and Risk Factors

What causes Jamestown syndrome?

The disease is caused by the gram‑negative, facultative intracellular bacterium Burkholderia pseudomallei. The organism is found in:

• Wet soils and stagnant water (rice paddies, marshes, flood‑plain areas).
• Surface water reservoirs, especially after heavy rains or cyclones.

Transmission occurs when the bacteria enter the body through:

• Skin abrasions or cuts (most common).
• Inhalation of aerosolized contaminated water or dust.
• Ingestion of contaminated water.
• Rarely, person‑to‑person spread (mostly via sexual contact or laboratory exposure).

Who is at higher risk?

• Occupational exposure: Farmers, rice paddy workers, construction workers, and military personnel deployed in endemic regions.
• Pre‑existing medical conditions: Diabetes mellitus (up to 50 % of cases), chronic kidney disease, chronic lung disease, and heavy alcohol use.
• Immunosuppression: HIV/AIDS, corticosteroid therapy, organ transplant recipients.
• Age: Both children and older adults are vulnerable, but severe disease is most common in adults >40 years.
• Environmental exposure: Recent heavy rain, flooding, or natural disasters increase the bacterial load in the environment.

Diagnosis

Timely diagnosis hinges on clinical suspicion plus laboratory confirmation. The diagnostic pathway usually follows these steps:

1. Clinical assessment

Physicians evaluate exposure history, risk factors, and the constellation of symptoms. A rapid, severe presentation in a traveler from an endemic area raises suspicion.

2. Laboratory tests

• Blood cultures: Positive in 40‑60 % of acute cases; the organism grows on standard media within 48 hours but may require selective agar.
• Culture of pus, sputum, urine, or cerebrospinal fluid (CSF): Direct isolation of B. pseudomallei provides definitive diagnosis.
• Serology: Indirect hemagglutination assay (IHA) or ELISA can support diagnosis, but antibodies may be absent early in infection.
• Molecular methods: PCR assays targeting the type III secretion system gene are rapid and increasingly available in reference labs.

3. Imaging studies

• Chest X‑ray or CT: Look for infiltrates, cavitations, or pleural effusions.
• Abdominal ultrasound/CT: Detect hepatic, splenic, or pancreatic abscesses.
• MRI of brain: Indicated if neurological symptoms suggest meningitis or brain abscess.

4. Diagnostic criteria

The CDC case definition for melioidosis requires isolation of Burkholderia pseudomallei from a normally sterile site, or a compatible clinical picture with a positive serologic or molecular test.

Treatment Options

Because the bacterium is intrinsically resistant to many antibiotics, therapy must be tailored to the organism’s susceptibility profile. Treatment is divided into two phases: an intensive “phase I” and a prolonged eradication “phase II”.

Phase I – Intensive therapy (10‑14 days)

• Intravenous ceftazidime 2 g every 6 h (or 50 mg/kg q6h) – the most widely used first‑line drug.
• Alternative IV agents: Meropenem (1 g q8h) or imipenem (500 mg q6h) for severe sepsis, CNS involvement, or ceftazidime intolerance.
• Supportive care: fluid resuscitation, vasopressors for shock, respiratory support if needed.

Phase II – Eradication therapy (3‑6 months)

• Oral trimethoprim‑sulfamethoxazole (TMP‑SMX) 8/40 mg kg⁻¹ twice daily for at least 12 weeks; most guidelines recommend 20–24 weeks for deep‑tissue infections.
• Doxycycline 100 mg bid can be added for patients unable to tolerate TMP‑SMX.
• Therapeutic drug monitoring is advised for renal impairment.

Adjunctive measures

• Surgical drainage: Required for large abscesses, empyema, or osteomyelitis.
• Intensive care support: Mechanical ventilation, renal replacement therapy, or intra‑abdominal pressure monitoring in critical cases.
• Patient education: Emphasize adherence to the prolonged oral regimen to prevent relapse.

Living with Jamestown syndrome (Acute melioidosis)

Even after successful treatment, many patients need ongoing management to reduce relapse risk and maintain quality of life.

Medication adherence

• Set daily reminders or use a pill‑box for the 3‑6‑month oral regimen.
• Report side‑effects (e.g., rash, neutropenia) promptly; dose adjustments may be necessary.

Follow‑up appointments

• First follow‑up 2 weeks after discharge to review labs (CBC, renal function) and wound healing.
• Monthly visits during eradication phase, with imaging (ultrasound/CT) if abscesses were present.

Physical activity & nutrition

• Gradual return to activity; avoid heavy lifting or soil exposure until wounds are fully healed.
• Balanced diet rich in protein to aid tissue repair; control blood glucose if diabetic.

Psychosocial support

• Consider counseling for anxiety or post‑traumatic stress after a severe infection.
• Support groups for melioidosis patients are available through the International Melioidosis Society.

Prevention

Because exposure is environmental, preventive strategies focus on reducing contact with contaminated soil or water.

• Protective clothing: Wear waterproof boots, gloves, and long sleeves when working in rice paddies, gardens, or during clean‑up after floods.
• Wound care: Promptly clean any cuts or abrasions with soap and clean water; apply an antiseptic dressing.
• Water safety: Avoid drinking untreated surface water; use filtration or boil water for at least 1 minute.
• Travel advice: Travelers to endemic regions should receive pre‑travel counseling and consider prophylactic antibiotics only under specialist guidance.
• Occupational health: Employers in high‑risk industries should provide education, personal protective equipment, and access to medical evaluation after exposure.

Complications

If left untreated or inadequately treated, acute melioidosis can lead to:

• Septic shock – multi‑organ failure with a mortality up to 40 %.
• Chronic suppurative infections – persistent abscesses in lungs, liver, spleen, prostate, or skin.
• Neurological sequelae – meningitis, brain abscess, or peripheral neuropathy.
• Relapse – occurs in up to 10‑15 % of patients who stop oral eradication therapy early.
• Long‑term disability – due to joint destruction or scarring from cutaneous lesions.

When to Seek Emergency Care

---

References:

1. World Health Organization. Melioidosis Fact Sheet. 2021.
2. CDC. Melioidosis – CDC. Updated 2023.
3. Wiersinga, WJ et al. “Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei.” *Nature Reviews Microbiology*, 2022.
4. Limmathurotsakul, D et al. “The global burden of melioidosis: estimating the incidence of this emerging tropical disease.” *Lancet Infectious Diseases*, 2020.
5. Cleveland Clinic. “Melioidosis (Burkholderia pseudomallei infection).” Patient Education, 2023.
6. Mahidol, T et al. “Clinical management of acute melioidosis.” *Clinical Infectious Diseases*, 2021.

```